Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Advanced Therapies Week 2022 | MOMENTUM: ARU-1801 in sickle cell disease

Will Chou, MD, Aruvant, New York, NY, presents preliminary results from the Phase I/II MOMENTUM study (NCT02186418) of ARU-1801, a lentiviral gene therapy, in patients with sickle cell disease (SCD). 5 patients are currently enrolled and the investigational therapy has a promising efficacy and safety profile, with no vaso-occlusive episodes (VOE) or hospital stays reported in patients. Dr Chou additionally reports a durable response in patients, with therapeutic hemoglobin detected in patients 3 years after initial administration. This interview took place at Advanced Therapies Week 2022.


Will Chou, MD, is an employee of Aruvant.